FDA chief Tukaram flags huge price gaps in medical devices, seeks Centre’s intervention
Source Entity
India Latest News: Top National Headlines Today & Breaking News | The Hindu
Maharashtra FDA Commissioner Tukaram Mundhe has urged the central government to regulate the massive price markups on medical devices. Investigations revealed extreme gaps between procurement costs and Maximum Retail Prices (MRP), leading to calls for stricter pharmaceutical pricing guidelines.
The Crisis of Medical Markup in India
Maharashtra Food and Drug Administration (FDA) Commissioner Tukaram Mundhe has brought to light a systemic issue within the Indian healthcare sector: the exorbitant disparity between the procurement cost of medical consumables and their Maximum Retail Price (MRP). By highlighting specific instances where an IV set purchased for ₹11.05 is marked up to ₹325, or a syringe costing under ₹7 is sold for ₹57, Mundhe has exposed a practice that he characterizes as a significant public health concern. This discrepancy suggests that the pricing structure for medical supplies is often disconnected from their actual manufacturing or distribution costs.
The 'Manipulated Raised Price' Phenomenon
The phenomenon often dubbed as 'Manipulated Raised Price' by critics reflects a lack of transparency that places an undue financial burden on patients. As Commissioner Mundhe noted, the most expensive components of a hospital bill are frequently those that the patient has no mechanism to verify. Because these markups are fixed long before a product reaches the clinical ward, the end-user—the patient—is left with no leverage or ability to negotiate, effectively trapping them in a cycle of inflated healthcare costs that can lead to medical debt or the postponement of essential treatment.
Regulatory Gaps and the Role of the NPPA
In response to these findings, Commissioner Mundhe has formally written to the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority (NPPA). The core of his recommendation involves establishing clear, legally binding guidelines regarding the permissible gap between trade procurement prices and the declared MRP. Currently, the lack of a standardized ceiling allows for these massive margins, which do not necessarily reflect value-added services but rather profit-driven pricing strategies that disadvantage the consumer.
Broader Implications for Healthcare Equity
This initiative by the Maharashtra FDA is part of a larger, ongoing effort to reform how private hospitals operate in India. Previous audits, such as those facilitated by the Jan Arogya Abhiyan, have corroborated these findings by comparing hospital procurement records against final patient billing. The implications are profound; if left unchecked, these practices undermine the affordability of critical care and erode public trust in the private healthcare system. By seeking central government intervention, Mundhe aims to standardize the pricing environment across state lines.
Future Trends and Policy Expectations
Looking ahead, the pressure to regulate medical device pricing is likely to intensify. As the central government reviews these recommendations, we may see a shift toward more stringent price caps on medical consumables, similar to the regulations already applied to essential medicines. If the NPPA adopts these guidelines, it could lead to a significant reduction in out-of-pocket healthcare expenses for millions of citizens. This move marks a pivotal step toward ensuring that the 'right to health' is supported by a fair and transparent economic framework for essential medical supplies.
Verification Required?